The increasing resistance of fungi to
antibiotics is a severe challenge in public health, and newly effective drugs are required. Promising potential medications are
lipopeptides, linear
antimicrobial peptides (AMPs) conjugated to a
lipid tail, usually at the N-terminus. In this paper, we investigated the in vitro and in vivo antifungal activity of three short myristoylated and non-myristoylated
peptides derived from a mutant of the
AMP Chionodracine. We determined their interaction with anionic and zwitterionic membrane-mimicking vesicles and their structure during this interaction. We then investigated their cytotoxic and hemolytic activity against mammalian cells. Lipidated
peptides showed a broad spectrum of activity against a relevant panel of pathogen fungi belonging to Candida spp., including the multidrug-resistant C. auris. The antifungal activity was also observed vs. biofilms of C. albicans, C. tropicalis, and C. auris. Finally, a pilot efficacy study was conducted on the in vivo model consisting of Galleria mellonella larvae. Treatment with the most-promising myristoylated
peptide was effective in counteracting the
infection from C. auris and C. albicans and the death of the larvae. Therefore, this myristoylated
peptide is a potential candidate to develop
antifungal agents against human fungal pathogens.